hydroxyurea has been researched along with Carcinoma, Non-Small Cell Lung in 18 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea 500 mg was given orally each Monday, Wednesday, Friday starting 1 week before paclitaxel, and continuing until removal from study." | 2.68 | Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer. ( Dulude, H; Evans, WK; Gertler, SZ; Goss, G; Huan, S; Logan, D; Stewart, DJ; Tomiak, EM; Yau, J, 1996) |
| "A case of a 69-year-old woman with myelofibrosis presenting with non-small cell lung cancer was reported at Sotiria General Hospital in Athens." | 1.36 | Bevacizumab may be active in myelofibrosis. ( Dilana, K; Makrilia, N; Meletis, I; Nikolaidis, I; Stathopoulos, D; Syrigos, K; Xyla, V, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 7 (38.89) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mijatovic, T | 1 |
| Jungwirth, U | 1 |
| Heffeter, P | 1 |
| Hoda, MA | 1 |
| Dornetshuber, R | 1 |
| Kiss, R | 1 |
| Berger, W | 1 |
| Nikolaidis, I | 1 |
| Makrilia, N | 1 |
| Xyla, V | 1 |
| Dilana, K | 1 |
| Stathopoulos, D | 1 |
| Meletis, I | 1 |
| Syrigos, K | 1 |
| Shinmura, K | 1 |
| Tao, H | 1 |
| Nagura, K | 1 |
| Goto, M | 1 |
| Matsuura, S | 1 |
| Mochizuki, T | 1 |
| Suzuki, K | 1 |
| Tanahashi, M | 1 |
| Niwa, H | 1 |
| Ogawa, H | 1 |
| Sugimura, H | 1 |
| Biard, DS | 1 |
| Miccoli, L | 1 |
| Despras, E | 1 |
| Harper, F | 1 |
| Pichard, E | 1 |
| Créminon, C | 1 |
| Angulo, JF | 1 |
| Durdux, C | 1 |
| Backlund, MG | 1 |
| Amann, JM | 1 |
| Johnson, DH | 1 |
| Edelman, MJ | 1 |
| Watson, D | 1 |
| Wang, X | 1 |
| Morrison, C | 1 |
| Kratzke, RA | 1 |
| Jewell, S | 1 |
| Hodgson, L | 1 |
| Mauer, AM | 1 |
| Gajra, A | 1 |
| Masters, GA | 1 |
| Bedor, M | 1 |
| Vokes, EE | 4 |
| Green, MJ | 1 |
| Haraf, DJ | 2 |
| Drinkard, LC | 1 |
| Hoffman, PC | 3 |
| Ferguson, MK | 3 |
| Vogelzang, NJ | 1 |
| Watson, S | 1 |
| Lane, NJ | 1 |
| Golomb, HM | 3 |
| Zauber, NP | 1 |
| Vlad, LD | 1 |
| Bitran, JD | 2 |
| Stewart, DJ | 1 |
| Tomiak, EM | 1 |
| Goss, G | 1 |
| Gertler, SZ | 1 |
| Logan, D | 1 |
| Huan, S | 1 |
| Yau, J | 1 |
| Dulude, H | 1 |
| Evans, WK | 1 |
| Kaba, SE | 1 |
| Kyritsis, AP | 1 |
| Hess, K | 1 |
| Yung, WK | 1 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Jaeckle, KA | 1 |
| Levin, VA | 1 |
| Mac Manus, MP | 1 |
| Cavalleri, G | 1 |
| Ball, DL | 1 |
| Beasley, M | 1 |
| Rotstein, H | 1 |
| McKay, MJ | 1 |
| Lad, T | 1 |
| Schor, J | 1 |
| Mullane, M | 1 |
| Carroll, R | 1 |
| Chernicoff, D | 1 |
| Blough, R | 1 |
| Weidner, L | 1 |
| Vijayakumar, S | 1 |
| Krishnasamy, S | 1 |
| Jacobs, R | 1 |
| Cantwell, BM | 1 |
| Veale, D | 1 |
| Rivett, C | 1 |
| Ghani, S | 1 |
| Harris, AL | 1 |
| Belani, CP | 1 |
| Eisenberger, M | 1 |
| Van Echo, D | 1 |
| Hiponia, D | 1 |
| Aisner, J | 1 |
| Axelson, JA | 1 |
| Clark, RH | 1 |
| Dimitrov, NV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Study of Eicosanoid Pathway Modulators and Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer[NCT00070486] | Phase 2 | 140 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| 0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients[NCT00771953] | Phase 2 | 109 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For determining progression-free survival, progression was determined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progression was defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00771953)
Timeframe: From the date of randomization until the first date that recurrent or progressive disease is objectively documented.
| Intervention | days (Median) |
|---|---|
| Apricoxib Plus Docetaxel | 75 |
| Placebo Plus Docetaxel | 97 |
| Apricoxib Plus Pemetrexed | 103 |
| Placebo Plus Pemetrexed | 98 |
2 reviews available for hydroxyurea and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
[Cisplatin and derivatives with radiation therapy: for what clinical use?].
Topics: Animals; Anus Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Ph | 2004 |
Concomitant chemoradiotherapy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chicago; Cisplatin; | 1994 |
5 trials available for hydroxyurea and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1995 |
Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 1996 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Humans; | 1992 |
11 other studies available for hydroxyurea and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
The Na+/K+-ATPase is the Achilles heel of multi-drug-resistant cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma, Non-Small-Cell | 2009 |
Bevacizumab may be active in myelofibrosis.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizuma | 2010 |
Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell | 2011 |
Participation of kin17 protein in replication factories and in other DNA transactions mediated by high molecular weight nuclear complexes.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Division; Co | 2003 |
Novel strategies for the treatment of lung cancer: modulation of eicosanoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; C | 2008 |
Myeloproliferative disorders in two New Jersey families.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; beta-Thalassemia; Carcinoma, Non-Small-Cell Lung; Female; | 1995 |
Exacerbation, then clearance, of mutation-proven Darier's disease of the skin after radiotherapy for bronchial carcinoma: a case of radiation-induced epidermal differentiation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Calcium-Transporting ATPases; Carcino | 2001 |
5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1990 |
Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carc | 1989 |
Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis-Related Groups; Drug Evaluation; Female; Huma | 1987 |
cis-platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 1987 |